We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pilot Study to Explore the Role of Gut Flora in Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04099979
Recruitment Status : Recruiting
First Posted : September 23, 2019
Last Update Posted : September 5, 2021
Sponsor:
Information provided by (Responsible Party):
ProgenaBiome

Tracking Information
First Submitted Date September 20, 2019
First Posted Date September 23, 2019
Last Update Posted Date September 5, 2021
Actual Study Start Date March 2, 2020
Estimated Primary Completion Date March 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: September 20, 2019)		 Correlation of Microbiome to Psoriasis via Relative Abundance Found in Microbiome Sequencing [ Time Frame: 1 year ]
Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the gut microbiome. These data will then be correlated with specific Psoriasis types
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures
 (submitted: September 20, 2019)		 Validation of Sequencing Methods [ Time Frame: 1 year ]
To validate the methods used to sequence samples
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title A Pilot Study to Explore the Role of Gut Flora in Psoriasis
Official Title A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Psoriasis
Brief Summary This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Psoriasis.
Detailed Description The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to the information provided in surveys and in medical records regarding Psoriasis
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples With DNA
Description:
Stool Samples
Sampling Method Probability Sample
Study Population Patients 18 years of age or older who have been diagnoed with Psoriasis
Condition
  • Psoriasis
  • Psoriasis Vulgaris
  • Psoriasis Universalis
  • Psoriasis Face
  • Psoriasis Nail
  • Psoriatic Plaque
  • Psoriasis Diffusa
  • Psoriasis Punctata
  • Psoriasis Palmaris
  • Psoriasis Circinata
  • Psoriasis Annularis
  • Psoriasis Genital
  • Psoriasis of Scalp
  • Psoriasis Geographica
Intervention Other: No Intervention
There is no intervention for this study
Study Groups/Cohorts Psoriasis patients
Patients who have been diagnosed with Psoriasis
Intervention: Other: No Intervention
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: September 20, 2019)		 25
Original Estimated Enrollment Same as current
Estimated Study Completion Date July 2023
Estimated Primary Completion Date March 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  1. Signed informed consent by patient
  2. Male or female patients age 18 and older.
  3. Diagnosis of Psoriasis based on PSAI of greater than or equal to 12 at screening

Exclusion Criteria:

  1. Refusal by patient to sign informed consent form
  2. Treatment with antibiotics within 2 weeks prior to screening
  3. Treatment with probiotics within 6 weeks prior to screening
  4. History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.
  5. Postoperative stoma, ostomy, or ileoanal pouch
  6. Participation in any experimental drug protocol within the past 12 weeks
  7. Treatment with total parenteral nutrition
  8. Any clinically significant evidence of disease that could interfere with the subject's ability to enter the trial
  9. Inability of patient to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Sabine Hazan, MD 18053390549 drsabinehazan@progenabiome.com
Contact: Jordan Daniels, MS 18053390549 jordan@progenabiome.com
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT04099979
Other Study ID Numbers PRG-011
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: Undecided
Plan Description: Only aggregated and deidentified data will be shared with other researchers.
Current Responsible Party ProgenaBiome
Original Responsible Party Same as current
Current Study Sponsor ProgenaBiome
Original Study Sponsor Same as current
Collaborators Not Provided
Investigators
Principal Investigator: Sabine Hazan, MD ProgenaBiome
PRS Account ProgenaBiome
Verification Date September 2021